Background: Chimeric antigen receptor (CAR) T-cell therapy leverages the power of the patient’s own immune system by serving as a bridge to connect genetically modified T cells to the surface antigens of tumor cells based on targeted ligands. Clinical trials have demonstrated compelling overall...

Background: This article presents an overview of pediatric relapsed and refractory acute lymphoblastic leukemia (ALL) and chimeric antigen receptor (CAR) T-cell therapy in pediatric patients. Objectives: Acute and chronic post–CAR T-cell effects and considerations are discussed, along with...

In the 2015 Ken Burns documentary, Cancer: The Emperor of All Maladies , based on Siddhartha Mukherjee’s The Emperor of All Maladies , the 2011 nonfiction award-winning biography about cancer, we are introduced to the first pediatric patient who received an experimental cellular therapy at Children...

Background: Significant improvement in overall survival observed in patients on clinical trials and U.S. Food and Drug Administration approval of two chimeric antigen receptor (CAR) T-cell therapies have resulted in an increasing population of survivors who have undergone this therapy. Although...